DAY 2 - Saturday, Feb. 2, 2013

NEW HORIZONS FORUM

State of glaucoma therapy focus of keynote

San Francisco—This could be a banner year for breakthroughs in glaucoma care. New understanding of the central nervous system and the nature of glaucoma has advanced researchers to the verge of changing the standard of care in this leading cause of blindness. "We are not talking about an eye disease any more when we talk about glaucoma," said Louis B. Cantor, MD, chairman and professor of ophthalmology and director of glaucoma service at Indiana University, Indianapolis. » MORE

Devices changing glaucoma surgery equation

San Francisco–Surgical treatment for glaucoma already offers good efficacy, but adverse event rates remain too high for routine use in mild-to-moderate disease. New devices promise to change that equation, said Ike K. Ahmed, MD, FRCSC, assistant professor, University of Toronto, Ontario. » MORE

Why the need for glaucoma biomarkers?

San Francisco–Though glaucoma is an optic neuropathy, it is defined by changes in visual field characteristics, explained Jeffrey L. Goldberg, MD, PhD, professor of ophthalmology and director of research at the Shiley Eye Center, University of California, San Diego. And by the time the visual field has changed, the disease has already progressed. » MORE

Driving discovery to clinical success

San Francisco–Drug discovery is a wonderful experience. "When an experience works, it is very exciting," said Anthony P. Adamis, MD, vice president, global head of ophthalmology, Genentech. In 1994, he was in the forefront of vascular endothelial growth factor research. "We just saw those vessels shut down." But seeing vessels shut down in an experimental model is just the first step. » MORE